A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overweight or Obese Patients.

Trial Profile

A Randomized, Double-Blind, Parallel-Group, Multicenter, Multinational Study to Assess the Long-Term Effect, Over 1 Year, of Rimonabant 10 mg in Comparison With Rimonabant 20 mg After an Initial Treatment Period of 6 Months With Rimonabant 20 mg in Overweight or Obese Patients.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2011

At a glance

  • Drugs Rimonabant (Primary)
  • Indications Obesity
  • Focus Therapeutic Use
  • Acronyms MODERATO
  • Sponsors Sanofi
  • Most Recent Events

    • 19 Jun 2009 Actual end date (1 Feb 2009) added as reported by ClinicalTrials.gov.
    • 19 Jun 2009 Actual patient number (331) added as reported by ClinicalTrials.gov.
    • 05 Nov 2008 Sanofi-aventis have reported in a media release that development of rimonabant has been discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top